Exact Mass: 426.2518

Exact Mass Matches: 426.2518

Found 111 metabolites which its exact mass value is equals to given mass value 426.2518, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Oxatomide

1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-2,3-dihydro-1H-1,3-benzodiazol-2-one

C27H30N4O (426.2419)


R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AE - Piperazine derivatives D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents Oxatomide is a first-generation piperazine H1-antihistamine. D018926 - Anti-Allergic Agents Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin[1][2].

   

Prostaglandin PGE2 1-glyceryl ester

(2R)-2,3-Dihydroxypropyl (5Z)-7-[(1R,2R,3S)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid

C23H38O7 (426.2617)


2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain,1 and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.2 Incubation of 2-AG with COX-2 and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 2:1-glyceryl ester mixture in typical aqueous media. While the stability and metabolism of these prostaglandin products has been investigated,4 little is known about their intrinsic biological activity. [HMDB] 2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain,1 and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.2 Incubation of 2-AG with COX-2 and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 2:1-glyceryl ester mixture in typical aqueous media. While the stability and metabolism of these prostaglandin products has been investigated,4 little is known about their intrinsic biological activity.

   

Prostaglandin D2-1-glyceryl ester

2,3-Dihydroxypropyl (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoic acid

C23H38O7 (426.2617)


2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain, and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.1,2 Incubation of 2-AG with cyclooxygenase-2 (COX-2) and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. In RAW 264.7 cells, PGD2-2-glyceryl ester is the main COX metabolite.3 The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 mixture of the 1- and 2-glyceryl esters in typical aqueous media. While the stability and metabolism of these PG products have been investigated, little is known about their intrinsic biological activity. [HMDB] 2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain, and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.1,2 Incubation of 2-AG with cyclooxygenase-2 (COX-2) and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. In RAW 264.7 cells, PGD2-2-glyceryl ester is the main COX metabolite.3 The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 mixture of the 1- and 2-glyceryl esters in typical aqueous media. While the stability and metabolism of these PG products have been investigated, little is known about their intrinsic biological activity.

   

Prostaglandin PGE2 glyceryl ester

1,3-Dihydroxypropan-2-yl (5Z)-7-[(1S,2S,3S)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid

C23H38O7 (426.2617)


GE2 glycerol ester is a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. 2-Arachidonoyl glycerol (2-AG) has been isolated from porcine brain,1 and has been characterized as the natural endocannabinoid ligand for the CB1 receptor.2 Incubation of 2-AG with COX-2 and specific prostaglandin H2 (PGH2) isomerases in cell cultures and isolated enzyme preparations results in prostaglandin glycerol ester formation.3 The biosynthesis of PGH, PGD, PGE, PGF, and TXA-2-glyceryl ester compounds have all been documented. The 2-glyceryl ester moiety equilibrates rapidly (within minutes) with the more stable 1-glyceryl ester, producing a 10:90 2:1-glyceryl ester mixture in typical aqueous media. While the stability and metabolism of these prostaglandin products has been investigated,4 little is known about their intrinsic biological activity. Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. GE2 glycerol ester is a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons

   

Prostaglandin H2 2-glyceryl Ester

1,3-dihydroxypropan-2-yl (5Z)-7-[(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept-5-enoate

C23H38O7 (426.2617)


Prostaglandin H2 2-glyceryl Ester is also known as 2-Glyceryl-prostaglandin H2. Prostaglandin H2 2-glyceryl Ester is considered to be practically insoluble (in water) and relatively neutral. Prostaglandin H2 2-glyceryl Ester is an eicosanoid lipid molecule

   

Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-4-hydroxy-3-methoxy-alpha-(1-methylethyl)-

Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-4-hydroxy-3-methoxy-alpha-(1-methylethyl)-

C25H34N2O4 (426.2518)


   

Dual-release hydrocortisone

4-(2-tetradecanamidoethyl)phenyl sulfamate

C22H38N2O4S (426.2552)


   

MG(PGE2/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid

C23H38O7 (426.2617)


MG(PGE2/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(PGD2/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoic acid

C23H38O7 (426.2617)


MG(PGD2/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0/0:0)

(2S)-2,3-dihydroxypropyl (5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoate

C23H38O7 (426.2617)


MG(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/PGE2/0:0)

1,3-dihydroxypropan-2-yl (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoate

C23H38O7 (426.2617)


MG(0:0/PGE2/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/PGD2/0:0)

1,3-dihydroxypropan-2-yl (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoate

C23H38O7 (426.2617)


MG(0:0/PGD2/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0)

1,3-Dihydroxypropan-2-yl (5S,6S,7E,9E,11Z,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid

C23H38O7 (426.2617)


MG(0:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

Pierisformosin B

Pierisformosin B

C23H38O7 (426.2617)


   

(rel-5S,6R,8R,9R,10S,13R,14S,15R,16S)-6-acetoxy-9,16;15,16-diepoxy-13,14-dihydroxy-15-methoxylabdane|viteagnusin G

(rel-5S,6R,8R,9R,10S,13R,14S,15R,16S)-6-acetoxy-9,16;15,16-diepoxy-13,14-dihydroxy-15-methoxylabdane|viteagnusin G

C23H38O7 (426.2617)


   

Parviflorene H

Parviflorene H

C30H34O2 (426.2559)


   

(1E,4S,5E,7R)-2-O-acetyl-7-O-beta-D-glucopyranosylgermacra-1(10),5-diene

(1E,4S,5E,7R)-2-O-acetyl-7-O-beta-D-glucopyranosylgermacra-1(10),5-diene

C23H38O7 (426.2617)


   

angustifolimine

angustifolimine

C25H34N2O4 (426.2518)


   

anthogorgiene G

anthogorgiene G

C30H34O2 (426.2559)


   

(1E,4S,5E,7R)-6O-acetyl-7-O-beta-D-glucopyranosylgermacra-1(10),5-diene

(1E,4S,5E,7R)-6O-acetyl-7-O-beta-D-glucopyranosylgermacra-1(10),5-diene

C23H38O7 (426.2617)


   

19,23-dihydroxyprotylonolide

19,23-dihydroxyprotylonolide

C23H38O7 (426.2617)


   

8beta-hydroxy-15-malonyloxy-ent-labdan-18-oic acid

8beta-hydroxy-15-malonyloxy-ent-labdan-18-oic acid

C23H38O7 (426.2617)


   

Ile Pro Pro Thr

(2S,3R)-2-{[(2S)-1-{[(2S)-1-[(2S,3S)-2-amino-3-methylpentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-hydroxybutanoic acid

C20H34N4O6 (426.2478)


   

Ile Pro Thr Pro

(2S)-1-[(2S,3R)-2-{[(2S)-1-[(2S,3S)-2-amino-3-methylpentanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Ile Thr Pro Pro

(2S)-1-{[(2S)-1-[(2S,3R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxybutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Leu Pro Pro Thr

(2S,3R)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-4-methylpentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-hydroxybutanoic acid

C20H34N4O6 (426.2478)


   

Leu Pro Thr Pro

(2S)-1-[(2S,3R)-2-{[(2S)-1-[(2S)-2-amino-4-methylpentanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Leu Thr Pro Pro

(2S)-1-{[(2S)-1-[(2S,3R)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxybutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Pro Ile Pro Thr

(2S,3R)-3-hydroxy-2-{[(2S)-1-[(2S,3S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]pentanoyl]pyrrolidin-2-yl]formamido}butanoic acid

C20H34N4O6 (426.2478)


   

Pro Ile Thr Pro

(2S)-1-[(2S,3R)-3-hydroxy-2-[(2S,3S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]pentanamido]butanoyl]pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Pro Leu Pro Thr

(2S,3R)-3-hydroxy-2-{[(2S)-1-[(2S)-4-methyl-2-[(2S)-pyrrolidin-2-ylformamido]pentanoyl]pyrrolidin-2-yl]formamido}butanoic acid

C20H34N4O6 (426.2478)


   

Pro Leu Thr Pro

(2S)-1-[(2S,3R)-3-hydroxy-2-[(2S)-4-methyl-2-[(2S)-pyrrolidin-2-ylformamido]pentanamido]butanoyl]pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Pro Pro Ile Thr

(2S,3R)-3-hydroxy-2-[(2S,3S)-3-methyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}pentanamido]butanoic acid

C20H34N4O6 (426.2478)


   

Pro Pro Leu Thr

(2S,3R)-3-hydroxy-2-[(2S)-4-methyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}pentanamido]butanoic acid

C20H34N4O6 (426.2478)


   

Pro Pro Thr Ile

(2S,3S)-2-[(2S,3R)-3-hydroxy-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}butanamido]-3-methylpentanoic acid

C20H34N4O6 (426.2478)


   

Pro Pro Thr Leu

(2S)-2-[(2S,3R)-3-hydroxy-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}butanamido]-4-methylpentanoic acid

C20H34N4O6 (426.2478)


   

Pro Thr Ile Pro

(2S)-1-[(2S,3S)-2-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]-3-methylpentanoyl]pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Pro Thr Leu Pro

(2S)-1-[(2S)-2-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Pro Thr Pro Ile

(2S,3S)-2-{[(2S)-1-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanoyl]pyrrolidin-2-yl]formamido}-3-methylpentanoic acid

C20H34N4O6 (426.2478)


   

Pro Thr Pro Leu

(2S)-2-{[(2S)-1-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanoic acid

C20H34N4O6 (426.2478)


   

Thr Ile Pro Pro

(2S)-1-{[(2S)-1-[(2S,3S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylpentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Thr Leu Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-methylpentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Thr Pro Ile Pro

(2S)-1-[(2S,3S)-2-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-3-methylpentanoyl]pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Thr Pro Leu Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanoyl]pyrrolidine-2-carboxylic acid

C20H34N4O6 (426.2478)


   

Thr Pro Pro Ile

(2S,3S)-2-{[(2S)-1-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-methylpentanoic acid

C20H34N4O6 (426.2478)


   

Thr Pro Pro Leu

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-4-methylpentanoic acid

C20H34N4O6 (426.2478)


   

N,O-Didesmethylverapamil

N,O-Didesmethylverapamil

C25H34N2O4 (426.2518)


   

2-glyceryl-PGD2

9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoic acid 2-glyceryl ester

C23H38O7 (426.2617)


   

PGD2-G

9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoic acid 1(3)-glyceryl ester

C23H38O7 (426.2617)


   

2-glyceryl-PGE2

9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid 2-glyceryl ester

C23H38O7 (426.2617)


   

PGE2-G

9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid 1(3)-glyceryl ester

C23H38O7 (426.2617)


   

2-glyceryl-PGH2

9S,11R-epidioxy-15S-hydroxy-5Z,13E-prostadienoic acid 2-glyceryl ester

C23H38O7 (426.2617)


   

PGH2-G

9S,11R-epidioxy-15S-hydroxy-5Z,13E-prostadienoic acid 1(3)-glyceryl ester

C23H38O7 (426.2617)


   

Methylcarbamyl PAF C-8

1-O-octyl-2-O-(N-methylcarbamoyl)-sn-glyceryl-3-phosphorylcholine

C18H39N2O7P (426.2495)


   

1-PGE(,2)-g

(2R)-2,3-dihydroxypropyl (5Z)-7-[(1R,2R,3S)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoate

C23H38O7 (426.2617)


   

PGD2-1-Glyceryl ester

2,3-dihydroxypropyl (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoate

C23H38O7 (426.2617)


   

FA 23:4;O5

9S,11R-epidioxy-15S-hydroxy-5Z,13E-prostadienoic acid 2-glyceryl ester

C23H38O7 (426.2617)


   

2-benzofuran-1,3-dione,2-[2-(2-hydroxyethoxy)ethoxy]ethanol,2,2,4-trimethylhexane

2-benzofuran-1,3-dione,2-[2-(2-hydroxyethoxy)ethoxy]ethanol,2,2,4-trimethylhexane

C23H38O7 (426.2617)


   

DU-14

Sulfamic acid, 4-(2-((1-oxotetradecyl)amino)ethyl)phenyl ester

C22H38N2O4S (426.2552)


   

quinine valerate

quinine valerate

C25H34N2O4 (426.2518)


   

oxatomide

oxatomide

C27H30N4O (426.2419)


R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AE - Piperazine derivatives D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents D018926 - Anti-Allergic Agents Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin[1][2].

   

Prostaglandin D2-1-glyceryl ester

Prostaglandin D2-1-glyceryl ester

C23H38O7 (426.2617)


   

prostaglandin E2 1-glyceryl ester

prostaglandin E2 1-glyceryl ester

C23H38O7 (426.2617)


A 1-monoglyceride resulting from the condensation of the carboxy group of prostaglandin E2 with the 1-hydroxy group of glycerol.

   

MG(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0/0:0)

MG(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0/0:0)

C23H38O7 (426.2617)


   

MG(0:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0)

MG(0:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/0:0)

C23H38O7 (426.2617)


   

N-[3-(diethylamino)propyl]-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide

N-[3-(diethylamino)propyl]-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide

C21H30N8O2 (426.2492)


   

(3aS,5S,9aS)-2-[(2-methylphenyl)methyl]-5-(1-methyl-3-phenyl-4-pyrazolyl)-3a,4,5,7,8,9-hexahydro-3H-pyrrolo[3,4-h]pyrrolizin-1-one

(3aS,5S,9aS)-2-[(2-methylphenyl)methyl]-5-(1-methyl-3-phenyl-4-pyrazolyl)-3a,4,5,7,8,9-hexahydro-3H-pyrrolo[3,4-h]pyrrolizin-1-one

C27H30N4O (426.2419)


   

1,3-dihydroxypropan-2-yl (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate

1,3-dihydroxypropan-2-yl (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate

C23H38O7 (426.2617)


   

1-(4-Azidobenzyl)-4-[2-(diphenylmethoxy)ethyl]piperidine

1-(4-Azidobenzyl)-4-[2-(diphenylmethoxy)ethyl]piperidine

C27H30N4O (426.2419)


   

2-glyceryl-Prostaglandin H2

2-glyceryl-Prostaglandin H2

C23H38O7 (426.2617)


   

2-glyceryl-Prostaglandin D2

2-glyceryl-Prostaglandin D2

C23H38O7 (426.2617)


   

2-glyceryl-Prostaglandin E2

2-glyceryl-Prostaglandin E2

C23H38O7 (426.2617)


   

Prostaglandin PGE2 glyceryl ester

Prostaglandin PGE2 glyceryl ester

C23H38O7 (426.2617)


   

Prostaglandin PGE2 1-glyceryl ester

Prostaglandin PGE2 1-glyceryl ester

C23H38O7 (426.2617)


   

prostaglandin I2 2-glyceryl ester

prostaglandin I2 2-glyceryl ester

C23H38O7 (426.2617)


A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin I2 with the 2-hydroxy group of glycerol.

   

Prostaglandin H2 2-glyceryl Ester

Prostaglandin H2 2-glyceryl Ester

C23H38O7 (426.2617)


A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin H2 with the 2-hydroxy group of glycerol.

   

prostaglandin D2 1-glyceryl ester

prostaglandin D2 1-glyceryl ester

C23H38O7 (426.2617)


A 1-monoglyceride resulting from the condensation of the carboxy group of prostaglandin D2 with the 1-hydroxy group of glycerol.

   

prostaglandin D2 2-glyceryl ester

prostaglandin D2 2-glyceryl ester

C23H38O7 (426.2617)


A 2-monoglyceride resulting from the condensation of the carboxy group of prostaglandin D2 with the 2-hydroxy group of glycerol.

   

prostaglandin E2 2-glyceryl ester

prostaglandin E2 2-glyceryl ester

C23H38O7 (426.2617)


A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin E2 with the 2-hydroxy group of glycerol.

   

1-Glyceryl-PGE2

1-Glyceryl-PGE2

C23H38O7 (426.2617)


   

Glyceryl-PGE2

Glyceryl-PGE2

C23H38O7 (426.2617)


   

ST 23:1;O2;S

ST 23:1;O2;S

C23H38O5S (426.244)


   
   

SB269652

SB269652

C27H30N4O (426.2419)


SB269652 is the first drug-like allosteric modulator of the dopamine D2 receptor (D2R); a new chemical probe that can differentiate D2R monomers from dimers or oligomers depending on the observed pharmacology. IC50 value: 0.2/0.5 nM [1] Target: D3 receptor antagonist SB269,652 potently (low nanomolar range) abolished specific binding of [(3)H]nemanopride and [(3)H]spiperone to Chinese hamster ovary-transfected D(3) receptors when radioligands were used at 0.2 and 0.5 nM, respectively. However, even at high concentrations (5 μM), SB269,652 only submaximally inhibited the specific binding of these radioligands when they were employed at 10-fold higher concentrations. By analogy, although SB269,652 potently blocked D(3) receptor-mediated activation of Gα(i3) and phosphorylation of extracellular-signal-regulated kinase (ERK)1/2, when concentrations of dopamine were increased by 10-fold, from 1 μM to 10 μM, SB269,652 only submaximally inhibited dopamine-induced stimulation of Gα(i3) [1].

   

(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[(1r,2e,4s,7e)-4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl]oxy}oxan-3-yl acetate

(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[(1r,2e,4s,7e)-4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl]oxy}oxan-3-yl acetate

C23H38O7 (426.2617)


   

5,5'-diisopropyl-3,3',8,8'-tetramethyl-[2,2'-binaphthalene]-1,1'-diol

5,5'-diisopropyl-3,3',8,8'-tetramethyl-[2,2'-binaphthalene]-1,1'-diol

C30H34O2 (426.2559)


   

(2s,2'r,3s,3ar,4'r,4'as,6r,7ar,8'as)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

(2s,2'r,3s,3ar,4'r,4'as,6r,7ar,8'as)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

C23H38O7 (426.2617)


   

[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-{[(1r,2e,4s,7e)-4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl]oxy}oxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-{[(1r,2e,4s,7e)-4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl]oxy}oxan-2-yl]methyl acetate

C23H38O7 (426.2617)


   

(2s,2's,3r,3as,4's,4'ar,6s,7ar,8'ar)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

(2s,2's,3r,3as,4's,4'ar,6s,7ar,8'ar)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

C23H38O7 (426.2617)


   

asebotoxin i

NA

C23H38O7 (426.2617)


{"Ingredient_id": "HBIN017046","Ingredient_name": "asebotoxin i","Alias": "NA","Ingredient_formula": "C23H38O7","Ingredient_Smile": "CCC(=O)OC1C2CCC3C1(CC(C4(C(C3(C)O)CC(C4(C)C)O)O)O)CC2(C)O","Ingredient_weight": "426.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1848","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "135929163","DrugBank_id": "NA"}

   

4,5-dihydroxy-6-(hydroxymethyl)-2-[(4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl)oxy]oxan-3-yl acetate

4,5-dihydroxy-6-(hydroxymethyl)-2-[(4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl)oxy]oxan-3-yl acetate

C23H38O7 (426.2617)


   

methyl (1r,2s,6s,15s,16r)-9-(ethylamino)-11-(2-hydroxyethyl)-2,15-dimethyl-18-oxo-4-azapentacyclo[11.4.1.0⁴,¹⁶.0⁶,¹⁵.0¹⁰,¹⁴]octadeca-9,11,13-triene-12-carboxylate

methyl (1r,2s,6s,15s,16r)-9-(ethylamino)-11-(2-hydroxyethyl)-2,15-dimethyl-18-oxo-4-azapentacyclo[11.4.1.0⁴,¹⁶.0⁶,¹⁵.0¹⁰,¹⁴]octadeca-9,11,13-triene-12-carboxylate

C25H34N2O4 (426.2518)


   

3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

C23H38O7 (426.2617)


   

(2r,3s,4s,5r,6r)-3,4,5-trimethoxy-2-(methoxymethyl)-6-{[(2s,3s,4s)-1,3,4,5-tetramethoxypentan-2-yl]oxy}oxane

(2r,3s,4s,5r,6r)-3,4,5-trimethoxy-2-(methoxymethyl)-6-{[(2s,3s,4s)-1,3,4,5-tetramethoxypentan-2-yl]oxy}oxane

C19H38O10 (426.2465)


   

(2s,3r,4s,5s,6r)-3-(acetyloxy)-5-hydroxy-6-methyl-2-({2-[(1r)-4-methylcyclohex-3-en-1-yl]propan-2-yl}oxy)oxan-4-yl (2s)-2-methylbutanoate

(2s,3r,4s,5s,6r)-3-(acetyloxy)-5-hydroxy-6-methyl-2-({2-[(1r)-4-methylcyclohex-3-en-1-yl]propan-2-yl}oxy)oxan-4-yl (2s)-2-methylbutanoate

C23H38O7 (426.2617)


   

(2r,2's,3r,3as,4's,4'ar,6s,7as,8'ar)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

(2r,2's,3r,3as,4's,4'ar,6s,7as,8'ar)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

C23H38O7 (426.2617)


   

3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

C23H38O7 (426.2617)


   

(1s,3r,4r,6s,8s,9r,10r,13r,14r,16s)-3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

(1s,3r,4r,6s,8s,9r,10r,13r,14r,16s)-3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

C23H38O7 (426.2617)


   

5-{5-[(2-carboxyacetyl)oxy]-3-methylpentyl}-6-hydroxy-1,4a,6-trimethyl-hexahydro-2h-naphthalene-1-carboxylic acid

5-{5-[(2-carboxyacetyl)oxy]-3-methylpentyl}-6-hydroxy-1,4a,6-trimethyl-hexahydro-2h-naphthalene-1-carboxylic acid

C23H38O7 (426.2617)


   

(1s,3r,4r,6s,8s,9r,10r,13r,14r,16r)-3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

(1s,3r,4r,6s,8s,9r,10r,13r,14r,16r)-3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

C23H38O7 (426.2617)


   

{3,4,5-trihydroxy-6-[(4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl)oxy]oxan-2-yl}methyl acetate

{3,4,5-trihydroxy-6-[(4-isopropyl-1,7-dimethylcyclodeca-2,7-dien-1-yl)oxy]oxan-2-yl}methyl acetate

C23H38O7 (426.2617)


   

(1s,13r,14s,17s,19s)-10-hydroxy-7-imino-13,14,18,18-tetramethyl-2-oxa-6-azapentacyclo[11.8.0.0¹,¹⁷.0³,¹¹.0⁴,⁸]henicosa-3(11),4(8),9-trien-19-yl acetate

(1s,13r,14s,17s,19s)-10-hydroxy-7-imino-13,14,18,18-tetramethyl-2-oxa-6-azapentacyclo[11.8.0.0¹,¹⁷.0³,¹¹.0⁴,⁸]henicosa-3(11),4(8),9-trien-19-yl acetate

C25H34N2O4 (426.2518)


   

3,4,5-trimethoxy-2-(methoxymethyl)-6-[(1,3,4,5-tetramethoxypentan-2-yl)oxy]oxane

3,4,5-trimethoxy-2-(methoxymethyl)-6-[(1,3,4,5-tetramethoxypentan-2-yl)oxy]oxane

C19H38O10 (426.2465)


   

10-hydroxy-7-imino-13,14,18,18-tetramethyl-2-oxa-6-azapentacyclo[11.8.0.0¹,¹⁷.0³,¹¹.0⁴,⁸]henicosa-3(11),4(8),9-trien-19-yl acetate

10-hydroxy-7-imino-13,14,18,18-tetramethyl-2-oxa-6-azapentacyclo[11.8.0.0¹,¹⁷.0³,¹¹.0⁴,⁸]henicosa-3(11),4(8),9-trien-19-yl acetate

C25H34N2O4 (426.2518)


   

(2r,3r,4s,5r,6s)-5-(acetyloxy)-4-hydroxy-2-methyl-6-({2-[(1r)-4-methylcyclohex-3-en-1-yl]propan-2-yl}oxy)oxan-3-yl (2s)-2-methylbutanoate

(2r,3r,4s,5r,6s)-5-(acetyloxy)-4-hydroxy-2-methyl-6-({2-[(1r)-4-methylcyclohex-3-en-1-yl]propan-2-yl}oxy)oxan-3-yl (2s)-2-methylbutanoate

C23H38O7 (426.2617)


   

(1s,3r,4r,6s,8s,9r,10r,13r,14r)-3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

(1s,3r,4r,6s,8s,9r,10r,13r,14r)-3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

C23H38O7 (426.2617)


   

(1s,3s,4r,6s,8s,9r,10r,13r,14r)-3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

(1s,3s,4r,6s,8s,9r,10r,13r,14r)-3,4,6,9,14-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl propanoate

C23H38O7 (426.2617)


   

(1s,4ar,5s,6s,8as)-5-[(3s)-5-[(2-carboxyacetyl)oxy]-3-methylpentyl]-6-hydroxy-1,4a,6-trimethyl-hexahydro-2h-naphthalene-1-carboxylic acid

(1s,4ar,5s,6s,8as)-5-[(3s)-5-[(2-carboxyacetyl)oxy]-3-methylpentyl]-6-hydroxy-1,4a,6-trimethyl-hexahydro-2h-naphthalene-1-carboxylic acid

C23H38O7 (426.2617)


   

(2r,2'r,3s,3ar,4'r,4'as,6r,7as,8'as)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

(2r,2'r,3s,3ar,4'r,4'as,6r,7as,8'as)-3,3a-dihydroxy-2-methoxy-2',5',5',8'a-tetramethyl-decahydro-2h,2'h-spiro[furo[2,3-b]pyran-6,1'-naphthalen]-4'-yl acetate

C23H38O7 (426.2617)